Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

OXiGENE and Boston Medical Center announce collaboration

Jan. 9, 1997

Vion receives SBIR grant to develop ribonucleotide reductase inhibitor

Jan. 9, 1997

KGF receptor antagonists developed by U.S. researchers

Jan. 9, 1997

BCH-4556 slated to enter clinical testing

Jan. 8, 1997

Pharmacyclics completes phase I testing of Lu-Tex

Jan. 8, 1997

Draxis acquires Canadian rights to Mylan's paclitaxel formulation

Jan. 8, 1997

New form of DNA linked to prostate cancer

Jan. 8, 1997

Joint venture formed to develop cancer therapy

Jan. 7, 1997

NeoRx technology receives additional patent

Jan. 7, 1997

p53 proteins with altered tetramerization domains synthesized

Jan. 7, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...